Navigation Links
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Date:4/26/2009

)."

Phase 3 Trial Design

The multicenter, randomized, double-blind, placebo-controlled Phase 3 study enrolled patients with unresectable stage III or stage IV melanoma at more than 200 clinical sites in the United States and Australia. The primary efficacy endpoint was overall survival, and secondary endpoints included progression-free survival and response rate.

Patients were randomized to receive 400 mg oral Nexavar twice daily or placebo, in addition to two chemotherapeutic agents - carboplatin and paclitaxel. Following 10 cycles of Nexavar or placebo plus chemotherapy, patients who achieved a response to the combination continued in a maintenance phase where Nexavar or placebo was administered as a single agent until disease progression.

About Melanoma

In 2007, more than 108,000 people worldwide (about 59,000 Americans) were diagnosed with melanoma and more than 40,000 of them (about 8,110 Americans) died from the disease. In the United States, the percentage of people who develop melanoma has more than doubled in the past 20 years. Melanoma accounts for about four percent of skin cancer cases but causes about 75 percent of skin cancer deaths.

Nexavar's Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is currently approved in more than 70 countries for the treatment of patients with liver cancer and in more than 80 countries for the treatment of patients with advanced kidney cancer. Nexavar is also being evaluated by the companies, international study groups, g
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
4. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
7. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
8. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
9. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
10. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  Rescheduling of hydrocodone combination ... the pain market, according to a new primary ... firm providing market research and consultation exclusively in ... - http://photos.prnewswire.com/prnh/20141021/153440 In ... hydrocodone combination products from Schedule III to Schedule ...
(Date:10/22/2014)... Antigen Discovery Inc. (ADi), a privately held ... the receipt of a National Institutes of Health (NIH) ... Institute of Dental and Craniofacial Research (NIDCR). The one-year ... Protein Microarray Chip, which will contain every protein in ... in the development of safe and effective vaccines and ...
(Date:10/22/2014)... , Oct. 22, 2014 Moms are ... health trackers for themselves and their kids, according to ... Report: Health & Fitness Go Mobile for Moms, the ... Series. BabyCenter, the number 1 pregnancy and parenting web ... that 55 percent of moms surveyed say they can,t ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4
... Israel, May 5, 2011 InspireMD, Inc. (OTC BB: NSPR) ... protective stent system, announced today that it has been approved ... Bulletin Board (OTCBB) under the symbol "NSPR". In ... PIPE offering in which (i) it raised approximately $9.0 million ...
... May 5, 2011 Spring Bank Pharmaceuticals today ... National Institute of Health, National Institute of Allergy and ... novel, orally bioavailable agent for the treatment of Hepatitis B ... award, Spring Bank Pharmaceuticals will receive $3.9 million over five ...
Cached Medicine Technology:InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 2InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 3InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 4InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 5Spring Bank Pharmaceuticals Awarded $3.9 Million RO1 NIH Grant to Advance Innovative Hepatitis Program 2
(Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... Ebola cases in Dallas. But, mental health specialists say overblown ... President Barack Obama on Friday appointed an Ebola "czar" to ... two Dallas nurses who cared for a Liberian man who ... But the U.S. cases are miniscule in the context ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... American Association for Homecare announced that it disagreed with ... them the provision to compel the transfer of ownership ... year and the suspension of home// health reimbursement are ... their stand, Tom Ryan, Chairman of the American Association ...
... Indian radiologist Rajeev Diddy is the only doctor of Indian origin ... He also has MD certifications to his credit. He sees as ... he calls it a day at 6 pm. His practice is ... achievement all the more creditable is the fact it has happened ...
... can also lead normal lives in a competitive world, ... University’s Saroj Saigal. Where educational achievements are concerned, // ... born prematurely, and those with a normal birth weight. ... of problems in behavior and academic achievement. ...
... entered into a joint venture with a South African company ... in Africa. //A joint venture between Ranbaxy and South Africa ... authority for this company to sell the drugs in Africa. ... this venture will permit the company to make the drugs ...
... of unscientific fears, according to a skier who is on ... published a report which states that second hand smoke (SHS) ... Most smokers consider the measures as attempts by the powerful ... ,The Utah Legislature is bei9ng called upon to ...
... to your heart’s content to remain fit and stay healthy. ... ,488 runners of the Boston marathon were tested for ... that more than one in eight had the condition. This ... exercise and then sodium levels in blood fall. ,This ...
Cached Medicine News:
... and quantification of proteinase 3 autoantibodies ... indirect immunofluorescence.Follow-up control of disease activity ... Anti-MPO-ELISA for detection of myeloperoxidase autoantibodies ... can be used from either of ...
... DYONICS POWERMAX Shaver Handpiece has 25% more ... standard Smith & Nephew handpiece providing optimal ... handling and reduced hand fatigue. ,The forward/reverse ... suction lever are all co-located to allow ...
... Light Source. , ... to provide every patient with ... through our ongoing research and ... and diagnostic solutions., ,At ...
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
Medicine Products: